Easy BIO

353810 · KOSDAQ · Consumer Staples · SMALL CAP

Revenue up 24.1% in FY2025.

Easy BIO reported consolidated results for FY2025: revenue of US$318M (+24.1% year on year), operating profit of US$30M (+38.8% year on year) and net income of US$19.5M (+47% year on year).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies))· FILED 2026-03-16· RCEPT 20260316902389

US$318MRevenue
+24.1%Revenue vs a year earlier
US$30MOperating profit

Converted at 1 USD ≈ ₩1,501.75 (filing-date rate, 2026-03-16 close)

What happened

Easy BIO reported consolidated results for FY2025: revenue of US$318M (+24.1% year on year), operating profit of US$30M (+38.8% year on year) and net income of US$19.5M (+47% year on year).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$318M
Revenue vs a year earlier+24.1%
Operating profitUS$30M
Net incomeUS$19.5M
PeriodFY2025 (consolidated)
Filed2026-03-16, Change of 30% or more in revenue or profit/loss structure (15% for large companies)
SourceDART rcept 20260316902389 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-03-16 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.